Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Sells $28,399.35 in Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director John Heinrich sold 4,773 shares of the business’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $5.95, for a total value of $28,399.35. Following the completion of the sale, the director now owns 75,167 shares in the company, valued at $447,243.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

John Heinrich also recently made the following trade(s):

• On Monday, May 20th, John Heinrich sold 15,227 shares of Sensus Healthcare stock. The stock was sold at an average price of $6.24, for a total value of $95,016.48.

Sensus Healthcare Stock Up 5.7 %

SRTS traded up $0.34 during trading on Friday, reaching $6.26. 221,836 shares of the company were exchanged, compared to its average volume of 392,373. The company has a market cap of $102.62 million, a price-to-earnings ratio of 21.59 and a beta of 0.92. Sensus Healthcare, Inc. has a 12-month low of $1.79 and a 12-month high of $6.55. The company’s 50-day moving average is $4.02 and its two-hundred day moving average is $3.38.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.18. The company had revenue of $10.66 million during the quarter, compared to analyst estimates of $4.33 million. Sensus Healthcare had a net margin of 14.70% and a return on equity of 9.76%. During the same period last year, the business earned ($0.12) earnings per share. Equities analysts forecast that Sensus Healthcare, Inc. will post 0.29 earnings per share for the current year.

Hedge Funds Weigh In On Sensus Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SRTS. Perritt Capital Management Inc. grew its holdings in shares of Sensus Healthcare by 5.0% during the third quarter. Perritt Capital Management Inc. now owns 105,586 shares of the company’s stock worth $292,000 after purchasing an additional 5,000 shares in the last quarter. Creekmur Asset Management LLC purchased a new position in Sensus Healthcare in the 4th quarter worth approximately $83,000. Hillsdale Investment Management Inc. bought a new position in shares of Sensus Healthcare in the 1st quarter worth $155,000. Finally, Sachetta LLC purchased a new stake in shares of Sensus Healthcare during the 4th quarter valued at $247,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on SRTS shares. HC Wainwright increased their target price on shares of Sensus Healthcare from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, May 13th. Maxim Group raised their price objective on shares of Sensus Healthcare from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, May 10th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.